1. Scrip
  2. >>Focus On Asia

India Compulsory Licensing: What USTR Hearing Transcripts Say

 
• By Anju Ghangurde

Private assurances or not, the prickly debate around the use of compulsory licenses in India appears to have an ongoing subtext going by the transcript of statements by the US-India Business Council (USIBC) before the United States Trade Representative (USTR) at the 2016 Special 301 review public hearing.

A US-India Business Council (USIBC) February statement to the office of the US Trade Representative concerning the 2016 Special 301 Review has raised a storm in India, after the business advocacy organization suggested that the Indian Government had privately reassured that India it would not use compulsory licenses for commercial purposes.

The Indian government has since denied such assurance, while the USIBC has issued a general clarification on its position around...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Focus On Asia

Sakaguchi’s Nobel Brings Cheer To Japan Biopharma

 
• By Lisa Takagi

Japan's latest Nobel Prize win sparks hopes for renewed investment in biopharma R&D by the national government, including in a venture co-founded by the winner.

India’s R&D Funding Push: Catalytic To De-Risking Early Innovation?

 
• By Anju Ghangurde

India rolls out amended R&D financial assistance plan targeting certain ‘priority areas’ and calls for proposals from industry and startups. While the corpus is modest, the scheme hopes to enable the ‘Innovate in India’ ecosystem and includes a co-funding provision.

Japan’s Cell Therapy Quest Goes On Despite Takeda, Novo Withdrawals

 
• By Lisa Takagi

Japan continues to see promise in iPSC and other cell therapies, despite two major firms recently announcing their withdrawal from the area and other setbacks.

Asia Deal Watch: Kyorin Collaborates On Hinge’s Multispecific Antibody For Lupus

 
• By Joseph Haas and Lisa Takagi

Plus deals involving Elix/Tohoku U., Hanmi/Gilead/Hope Health, Heartseed/Novo Nordisk, Novatim/VRise, Qurient/Synaffix, Huons/Therapex, Mochida/Itochu/AND Pharma, Sovargen/Angelini, Starpharma/Genentech, Axcelead/xFOREST and Daiichi Sankyo/Immuto.

More from Scrip

Zenas Looks To Target Progressive Multiple Sclerosis Via InnoCare Deal

 
• By Joseph Haas

Licensing a BTK inhibitor for progressive MS previously held by Biogen, Zenas says Phase III orelabrutinib can stave off disability related with disease progression.

Sanofi/Orano Look To Next Steps After Phase II Radiotherapy Success

 
• By Alaric DeArment

The companies announced positive Phase II results for AlphaMedix, a lead 212-based alpha emitter therapy for gastroenteropancreatic neuroendocrine tumors.

Psoriasis Submissions Iin The Bag, J&J Advances Icotrokinra Into Phase III For Ulcerative Colitis

 
• By Kevin Grogan

The company has presented the full set of positive results from the Phase IIb ANTHEM-UC trial in the inflammatory bowel disease.